Microchemistry Implant Device
Reporter: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2013/03/26/microchemistry-implant-device/
The world’s smallest implantable blood monitoring implant for early detection of acute coronary syndrome and other monitoring has been reported by the IFCC.
World’s smallest blood monitoring implant tells your smartphone when you’re about to have a heart attack
By John Hewitt on March 21, 2013
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
In announcing the world’s smallest medical implant to monitor critical chemicals in the blood, a 14mm device measures up to five indicators, including proteins like troponin, glucose, and lactate, scientists at Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland have developed a device that can measure and transmit the data to a smartphone for tracking. It is powered by a 100 milliwatts patch that the device requires by wireless inductive charging through the skin. Each sensor is coated with an enzyme that reacts with blood-borne chemicals to generate a detectable signal. For patient monitoring, a device like this would quickly become indispensable once introduced, especially for continuous dosage monitoring. This would be partcularly useful when patient’s ability to break down and excrete the drug is compromized by either impaired functioning of liver or kidney in drug elimination.
http://www.youtube.com/watch?feature=player_embedded&v=DBa41wej-NE
To be fail-safe, this depends on the patient having access to their data. Dependence on the integrity of multiple weak links to the cloud, to the doctor, and back again — as is often the prescribed future care scenario — are unacceptable, particularly when heart attacks might be counted on to occur precisely at those times when those links may not be there. Assuming the battles for patient rights will be won sooner rather than later, the next important choice would be getting the proper ringtone when that fateful troponin call comes.
Ions and respiratory gases in the blood at different body locations can also be mapped. When coupled with powerful analysis packages, a device like this could help make the patient the customer once again. For now, the device is limited to the lifetime of the enzymes — typically after a month or two they can be considered expired.
http://www.extremetech.com/wp-content/uploads/2013/03/EPFL-implant-300×264.jpg
As a final note, it should be observed that the EPFL device is not the only one on the horizon. Tricorder-style blood scanners are just beginning to gain a foothold in the medical community. A new $100 million research fund has just been announced by Blackberry mastermind Mike Lazaridis. The new fund is called Quantum Valley Investments, and is emphasizing all things quantum.
Related articles
- Small Blood Monitoring Implant Sends Information To User’s Smartphone Before a Heart Attack (mi021.wordpress.com)
- Your Phone’s Ringing – Because You’re Minutes from a Heart Attack (livescience.com)
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.